Goldman Sachs Asset Management led a Series D2 financing round in InferVision, a medical artificial intelligence provider specializing in the clinical application of AI and deep learning technologies. The company has raised around $140 million in total from Series D1 and D2 financing. The proceeds will be used for R&D, distribution channels expansion and business development.
Through AI-powered detection and triage systems, InferVision is focused on empowering clinicians with higher efficiency in disease prevention and control, while serving patients with more thorough diagnosis at lower costs. Using AI and deep learning technologies, InferVision is developing platforms including AI application management and data mining & research.
“While healthcare has undergone significant evolution, the application of AI technologies to accelerate medical diagnosis stands out as one of the most compelling opportunities to benefit and innovate for a large addressable market in the future,” said Xinyi Feng, a managing director in Goldman Sachs Asset Management. “We look forward to helping InferVision achieve this dynamic vision that could have a profound impact on healthcare.”
“We are excited to have a proven, global investor like Goldman Sachs lead this latest round of financing. We view the collaboration with them as recognition of our capabilities in developing advanced AI solutions in healthcare.” said Chen Kuan, founder and chairman of InferVision. “Our company aims to utilize rapidly evolving technology to bring about a significant improvement in medical services.”